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Abstract
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the
first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab
manufactured by ImClone (US commercial cetuximab) potentially results in higher systemic exposures than
cetuximab manufactured by Boehringer Ingelheim (BI-manufactured cetuximab). This prospective, randomized,
double-blind study compared the safety profiles of the two cetuximab formulations.
Methods: Patients with previously untreated locoregionally recurrent and/or metastatic SCCHN were randomly
assigned to receive the same dose of US commercial cetuximab (Arm A) or BI-manufactured cetuximab (Arm B),
each in combination with cisplatin or carboplatin plus 5-FU. The primary outcome was all-grade, all-cause
treatment-emergent adverse events (TEAEs).
Results: The majority of patients experienced ≥1 TEAE, regardless of causality (Arm A: 75/77 patients, 97.4 %; Arm
B: 68/71 patients, 95.8 %). TEAEs with the highest incidence included nausea, fatigue, and hypomagnesemia in both
arms. The absolute risk difference between the two arms for patients experiencing at least one adverse event (AE)
was 0.029 (p = 0.281, 95 % confidence interval [CI]: -0.024, 0.082) for AEs regardless of causality and 0.005 (p = 0.915,
95 % CI: -0.092, 0.103) for AEs possibly related to study drug. There were no significant differences between the two
arms in the incidence of acneiform rash, cardiac events, infusion reactions, or hypomagnesemia. Overall survival,
progression-free survival, and overall response rates were similar in the two arms.
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Conclusions: There were no clinically meaningful differences in safety between US commercial cetuximab and BI-
manufactured cetuximab in combination with platinum-based therapy with 5-FU in patients with locoregionally
recurrent and/or metastatic SCCHN. The use of US commercial cetuximab in this combination chemotherapy
regimen did not result in any unexpected safety signals. The efficacy results of this study are consistent with the
efficacy results of the cetuximab arm of the EXTREME study.
Trial registration: ClinicalTrials.gov NCT01081041; date of registration: March 3, 2010).
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Background
Head and neck cancer is the sixth most common cancer
worldwide, with more than 650,000 new cases diag-
nosed each year [1]. Treatment options for patients
with recurrent/metastatic squamous cell carcinoma of
the head and neck (SCCHN) are limited. Currently,
the standard of care (category 1 evidence) for recurrent/
metastatic SCCHN is the regimen used in the EXTREME
study (Erbitux in First-Line Treatment of Recurrent or
Metastatic Head and Neck Cancer), consisting of cetuxi-
mab in combination with cisplatin or carboplatin plus 5-
fluorouracil (5-FU) [2, 3]. Historically, median survival
with chemotherapy is approximately 6 months and the
1-year survival rate is approximately 20 % [2]. The
addition of cetuximab, an anti-epidermal growth factor
receptor (EGFR) monoclonal antibody, to cytotoxic
agents has shown a significant increase in response rate
[3, 4] and a significant survival benefit [3] in recurrent/
metastatic SCCHN.
In the EXTREME study, conducted in 17 European
countries, 442 patients with previously untreated
recurrent/metastatic SCCHN were randomized to re-
ceive chemotherapy alone (cisplatin or carboplatin plus
5-FU) or in combination with cetuximab [3]. There were
statistically significant and clinically meaningful im-
provements in all efficacy endpoints (overall survival
[OS], progression-free survival [PFS], and overall re-
sponse rate [ORR]) in the cetuximab plus chemotherapy
group compared with the chemotherapy-alone group.
Overall, the safety data from the EXTREME study indi-
cated that the addition of cetuximab to chemotherapy
did not affect tolerability and that the adverse event
(AE) profile for this cetuximab-chemotherapy regimen
was consistent with that expected for the agents used
[3]. Adverse events of interest for cetuximab include
acneiform rash, cardiac events, infusion reactions, and
hypomagnesemia [3, 5]. Based on the results of the
EXTREME study, cetuximab was approved by the
European Union (EU) for the treatment of patients
with SCCHN in combination with platinum-based
chemotherapy for recurrent and/or metastatic disease
[6], and later by the United States (US) Food and Drug
Administration (FDA) for the first-line treatment of
patients with recurrent locoregional disease or metastatic
SCCHN in combination with platinum-based therapy with
5-FU [5].
The cetuximab clinical supply for the EXTREME study
was manufactured by the Europe-based company
Boehringer Ingelheim (BI-manufactured cetuximab).
Population pharmacokinetic data indicate that cetuxi-
mab manufactured by the US-based company ImClone
(US commercial cetuximab) is associated with approxi-
mately 22 % higher systemic drug exposure relative to BI-
manufactured cetuximab, due to decreased clearance [5].
Due to the potential for increased exposure and the possi-
bility of a greater incidence and severity of adverse reac-
tions with US commercial cetuximab compared with BI-
manufactured cetuximab [5], a prospective study of the
two cetuximab formulations was conducted. This study
compared the safety profiles of US commercial cetuximab
and BI-manufactured cetuximab, each in combination
with cisplatin or carboplatin plus 5-FU (the regimen used
in the EXTREME study [3]), in patients with locoregion-
ally recurrent and/or metastatic SCCHN.
Methods
Study population
The patient eligibility criteria were similar to those of
the EXTREME study [3]. Patients with histologically or
cytologically confirmed locoregionally recurrent and/or
metastatic SCCHN not suitable for local therapy were
eligible for this study. Other eligibility criteria included:
age ≥18 years; measurable or evaluable disease, as de-
fined by Response Evaluation Criteria in Solid Tumors
(RECIST) version 1.0; Karnofsky Performance Status
(KPS) score of at least 70; and adequate hematologic,
renal, and hepatic function. Patients were excluded from
the study if they had: previous systemic chemotherapy,
unless required as part of multimodal treatment for lo-
cally advanced head and neck cancer that was completed
more than 4 months before study entry; previous treat-
ment with monoclonal antibody therapy, other signal
transduction inhibitors, or EGFR targeting therapy, ex-
cept for previous cetuximab treatment given as part of a
multimodal treatment for locally advanced head and
neck cancer that was completed more than 4 months
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before study entry; nasopharyngeal carcinoma; or other
concomitant anticancer therapies.
The study was conducted in hospital-based clinics in
North America. The study protocol was approved by the
ethics review board at each site (see below) and was
conducted in accordance with Good Clinical Practice
guidelines and the Declaration of Helsinki. All patients
provided written informed consent before undergoing
any study procedure. The study was registered at
www.clinicaltrials.gov (NCT01081041) [7].
Ethics review boards
The following ethics review boards approved the study
protocol: US Oncology, Western Institutional Review
Board, Washington University Medical Center, Dallas
VA Medical Center IRB, Committee for the Protection
of Human Subjects, Wayne State University, Wake
Forest University School of Medicine, Cleveland Clinic
of Weston Florida, University of Illinois College of
Medicine, Scott & White Institutional Review Board,
Decatur Memorial Hospital, Medical University of South
Carolina, Stratton VA Medical Center, Veterans Affairs
Medical Center, Medical College of Georgia, Translational
Research in Oncology-US Inc, Mount Sinai School of
Medicine Dermatology Clinical Trials, Comite Bioetico
para la Investigacion Clinica SC, Centro Anticanceroso
Cruz Roja Mexicana, Instituto Nacional de Cancerologia,
Centro Estatal de Cancerologia, Antiguo Hospital Civil
de Guadalajara, Ontario Cancer Research Ethics Board,
Alberta Health Services, and Comite D'Ethique De La
Recherche.
Study design
This was a multicenter, Phase 2 study with a single-arm,
open-label, 30-patient safety lead-in phase followed by a
two-arm, randomized, double-blind phase in patients
with locoregionally recurrent and/or metastatic SCCHN
who had not received prior systemic chemotherapy. The
30-patient lead-in phase was requested by the FDA to
assess the safety of US commercial cetuximab before
starting the randomized phase of the study.
Patients were randomly assigned to US commercial
cetuximab plus chemotherapy (Arm A) or BI-
manufactured cetuximab plus chemotherapy (Arm B)
in a 1:1 ratio (first patient enrolled: 08 June 2010).
Randomization was carried out using a computer-
generated random sequence and a centralized inter-
active voice response system (IVRS). To maintain the
blinding of patients and the personnel involved in
patient evaluations and data collection, an unblinded
third party was designated. The investigator provided
the necessary information to the unblinded designee
who then called the IVRS to obtain the patient’s
treatment assignment.
A minimization principle was used to balance patient
assignment between treatment arms, using a probability
factor of 0.75, based on the following factors: primary
tumor site (oral cavity/oropharynx vs other); previous
chemotherapy (yes vs no); previous cetuximab treatment
(yes vs no); KPS (<80 vs ≥80); intention to give cisplatin
or carboplatin; measurable vs evaluable disease; and par-
ticipating center.
Treatment protocol
Study drugs were administered intravenously in 21-day
cycles, with a 1-hour observation period between cetuxi-
mab and cisplatin/carboplatin, in the following order:
(i) cetuximab 400 mg/m2 (2-hour infusion) on Day 1
of Cycle 1 and 250 mg/m2 (1-hour infusion) weekly
thereafter; (ii) cisplatin 100 mg/m2 (1-hour infusion)
or carboplatin area under the concentration curve
(AUC) 5 mg/mL/min (1-hour infusion) on Day 1 of
Cycles 1 to 6; (iii) 5-FU 1000 mg/m2/day as a con-
tinuous infusion on Days 1 through 4 of Cycles 1 to 6.
Patients enrolled in the safety lead-in phase and patients
randomized to Arm A received US commercial cetuxi-
mab; patients randomized to Arm B received BI-
manufactured cetuximab. Patients received cisplatin or
carboplatin at the discretion of the investigator. Dose
modifications of cetuximab and chemotherapy were
permitted according to protocol-specified criteria. Pa-
tients who completed six cycles of combination therapy
continued to receive cetuximab monotherapy until dis-
ease progression, unacceptable toxicity, or any other
withdrawal criterion was met. If clinically indicated,
patients who discontinued chemotherapy prior to com-
pleting six cycles of combination therapy were permit-
ted to continue with cetuximab until a withdrawal
criterion was met. Patients who discontinued cetuximab
were permitted to continue with chemotherapy up to
six cycles.
Assessments
Adverse events were assessed according to the Common
Terminology Criteria for Adverse Events (CTCAE;
Version 4.0) and the Medical Dictionary for Regulatory
Activities (MedDRA; Version 16.0).
Tumor response was assessed using RECIST version
1.0. Tumor measurements were performed at baseline
and every two cycles by computed tomography or mag-
netic resonance imaging; chest x-ray was acceptable for
clearly defined lesions surrounded by aerated lung.
Outcomes
The primary objective of the study was to prospectively
compare the safety profiles of US commercial cetuximab
and BI-manufactured cetuximab with respect to indi-
vidual all-grade, all-cause treatment-emergent adverse
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events (TEAEs) occurring at any time during the
treatment period. A TEAE was defined as an event
that first appeared or an event already present that
worsened in severity following the first dose exposure
and up to 30 days after the last dose of study treat-
ment. Secondary objectives included overall safety,
OS, PFS, and ORR.
Statistical analysis
Planned enrollment was approximately 230 patients: 30
patients for the safety lead-in phase and 200 patients for
the two-arm, randomized, double-blind phase. The
sample size was based on practical and clinical consider-
ations to ensure that the safety profile could be appro-
priately compared between the two treatment arms and
was not based on any statistical assumptions or
hypotheses.
For the safety lead-in phase, the safety and efficacy
analyses were conducted on the safety lead-in popula-
tion, which consisted of all patients enrolled in this
phase of the study. For the randomized phase, the safety
and efficacy analyses were conducted on the randomized
and treated (RT) population, which consisted of all
patients in the two-arm, randomized, double-blind
phase of the study who received at least one dose of
any of the study drugs (cetuximab, cisplatin/carboplatin,
and 5-FU).
The primary outcome was all-grade, all-cause TEAEs
in the RT population. The risk difference for the occur-
rence of each AE was calculated and the 95 % confi-
dence interval (CI) and p value were generated using
normal approximation. The false discovery rate method
of multiplicity adjustment was applied to control the
type I error (the false positive rate) when comparing in-
dividual AEs. Adverse events of special interest were
hypomagnesemia and the composite terms acneiform
rash, cardiac event, and infusion reaction. Exposure to
cetuximab and chemotherapy was reported as median
duration plus 25th and 75th percentiles and relative dose
intensity (actual dose delivered as a percentage of
planned dose). Overall survival was defined as the time
from randomization to death; PFS was defined as the
time from randomization to the first objective progres-
sion of disease or death. The Kaplan-Meier method was
used to estimate median OS and PFS. Log-rank and
Wilcoxon statistics were calculated to provide between-
treatment comparisons unadjusted for covariates for OS
and PFS. The ORR was calculated as the percentage of
patients with a confirmed (within 28 days) best response
of complete response (CR) or partial response (PR). The
disease control rate (DCR) was calculated as the per-
centage of patients with a confirmed best response of
CR, PR, or stable disease. Analyses were performed
using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Because of manufacturing process changes, Boehringer
Ingelheim stopped manufacturing the cetuximab formu-
lation used in the EXTREME study. The supply of BI-
manufactured cetuximab expired during the study
period; upon expiration, ongoing patients in Arm B
were switched to US commercial cetuximab. For the
primary safety analysis, the data analysis cut-off date
was the earliest date that a patient in Arm B was
switched from BI-manufactured cetuximab to US
commercial cetuximab (23 January 2013). For the effi-
cacy analyses, the data analysis cut-off date was the
date that the reporting database was locked for ana-
lysis (27 September 2013). For any patient in Arm B
who was switched from BI-manufactured cetuximab
to US commercial cetuximab, OS and PFS were cen-
sored at the time of the switch.
Results
Patient disposition
A total of 33 patients were enrolled in the safety lead-in
phase of the study and constituted the safety lead-in
population. As the safety and efficacy results for the
safety lead-in population were consistent with those for
Arm A in the RT population (both of which received US
commercial cetuximab), the results for this population
are not presented here. In total, 81 patients were ran-
domly assigned to US commercial cetuximab plus
chemotherapy (Arm A) and 73 patients were randomly
assigned to BI-manufactured cetuximab plus chemother-
apy (Arm B) in the two-arm, randomized, double-blind
phase of the study (Fig. 1). Of these, 77 patients in Arm
A and 71 patients in Arm B received at least one dose of
any study drug and constituted the RT population. In
Arm B, 9/71 patients (12.7 %) switched from BI-
manufactured cetuximab to US commercial cetuximab
following the expiration of BI-manufactured cetuximab.
Demographic and baseline clinical characteristics
Baseline characteristics were mostly similar between
Arm A and Arm B (Table 1). The majority of patients in
the RT population were male (Arm A: 68/77 patients,
88.3 %; Arm B: 55/71 patients, 77.5 %). Median age was
57.8 and 61.3 years in Arm A and Arm B, respectively.
The primary tumor site was the oral cavity/oropharynx
in 48/77 patients (62.3 %) in Arm A and 45/71 patients
(63.4 %) in Arm B, and the larynx/hypopharynx in 18/77
patients (23.4 %) in Arm A and 13/71 patients (18.3 %)
in Arm B.
Exposure to cetuximab and chemotherapy
Overall, the treatment durations of cetuximab and
chemotherapy were mostly similar between Arm A and
Arm B (Table 2). The relative dose intensity of cetuxi-
mab, cisplatin, and 5-FU was similar in the two arms;
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the relative dose intensity of carboplatin was numerically
higher in Arm A than Arm B (94.3 % vs 88.4 %).
Safety
There were no clinically meaningful differences in safety
between Arm A and Arm B, as assessed by incidence of
(i) all-grade, all-cause TEAEs (the primary objective of
the study), (ii) maximum CTCAE grade AEs regardless
of causality, and (iii) maximum CTCAE grade AEs pos-
sibly related to study drug.
All-grade, all-cause TEAEs
The majority of patients in both arms experienced at
least 1 TEAE, regardless of causality: 75/77 patients
(97.4 %) in Arm A and 68/71 patients (95.8 %) in Arm B
(Table 3). The TEAEs with the highest incidence in the
two arms included nausea (Arm A: 38/77 patients,
49.4 %; Arm B: 34/71 patients, 47.9 %), fatigue (Arm A:
35/77 patients, 45.5 %; Arm B: 36/71 patients, 50.7 %),
and hypomagnesemia (Arm A: 29/77 patients, 37.7 %;
Arm B: 29/71 patients, 40.8 %). There were no signifi-
cant differences between Arm A and Arm B in the inci-
dence of any individual TEAE, apart from the incidence
of rash, which was significantly lower in Arm A than
Fig. 1 Patient flow. Abbreviations: BI = Boehringer Ingelheim; RT = randomized and treated; US = United States











Male 68 (88.3) 55 (77.5)
Age, years
Median (range) 57.8 (26.9–77.2) 61.3 (29.2–81.9)
KPS score, n (%)
70 9 (11.7) 7 (9.9)
80 28 (36.4) 22 (31.0)
90 32 (41.6) 31 (43.7)
100 8 (10.4) 11 (15.5)
Stage of disease, n (%)
Local 8 (10.4) 12 (16.9)
Locoregional 26 (33.8) 20 (28.2)
Metastatic 43 (55.8) 38 (53.5)
Histologic type, n (%)
Well differentiated 3 (3.9) 6 (8.5)
Moderately differentiated 35 (45.5) 29 (40.8)
Poorly differentiated 25 (32.5) 17 (23.9)
Undifferentiated 3 (3.9) 1 (1.4)
Unable to determine 11 (14.3) 15 (21.1)
Missing/unknown 0 2 (2.8)
Abbreviations: BI Boehringer Ingelheim, KPS Karnofsky Performance Status,
US United States
Table 2 Summary of treatment exposure








Median duration of treatment
(25th percentile, 75th percentile),
weeks
Cetuximab 12.4 (6.0, 18.0) 13.6 (6.0, 20.0)
Cisplatin 6.9 (3.0, 14.0) 9.0 (3.0, 18.0)
Carboplatin 12.6 (6.1, 18.0) 15.0 (7.0, 20.0)
5-FU 13.0 (6.0, 17.9) 13.0 (6.3, 20.0)





Abbreviations: 5-FU 5-fluorouracil, BI Boehringer Ingelheim, US United States
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Arm B. The TEAE of rash was reported in 10/77 pa-
tients (13.0 %) in Arm A and 19/71 patients (26.8 %) in
Arm B (p = 0.034, 95 % CI: 0.010, 0.265).
Analysis of adverse events by maximum CTCAE grade
When AEs were analyzed by maximum CTCAE grade,
the percentage of patients who experienced at least 1 AE
regardless of causality was similar in the two arms: 76/
77 patients (98.7 %) in Arm A and 68/71 patients
(95.8 %) in Arm B (absolute risk difference between the
two arms: 0.029; p = 0.281, 95 % CI: -0.024, 0.082). The
incidence of bone pain, febrile neutropenia, laryngeal
hemorrhage, somnolence, and syncope was significantly
lower in Arm A than Arm B (Table 4). The percentage
of patients who experienced at least 1 AE possibly
related to study drug was also similar in the two arms:
69/77 patients (89.6 %) in Arm A and 64/71 patients
(90.1 %) in Arm B (absolute risk difference between the
two arms: 0.005; p = 0.915, 95 % CI: -0.092, 0.103). The
incidence of dysguesia and febrile neutropenia possibly
related to study drug was significantly lower in Arm A
than Arm B (Table 4).
Adverse events of special interest for cetuximab treatment
There were no significant differences between Arm A
and Arm B in the incidence of acneiform rash, cardiac
events, infusion reactions, or hypomagnesemia (Table 5).
A little over half of the patients in each arm reported
acneiform rash possibly related to study drug, mostly
grade 1 or 2 in severity. Grade 3 skin reactions possibly
related to study drug were dermatitis acneiform (Arm A:
4/77 patients, 5.2 %; Arm B: 4/71 patients, 5.6 %) and
rash (Arm A: no patients; Arm B: 3/71 patients, 4.2 %).
Two patients in Arm A died of cardiac arrest; one death
from cardiac arrest was considered possibly related to
study drug. No grade 3 or 4 cardiac events were re-
ported in Arm A and no grade 4 or 5 cardiac events
were reported in Arm B. Few patients reported grade 3
or 4 infusion reactions (Table 6). In Arm A, 2 patients
(2.6 %) experienced grade 4 anaphylactic shock and 1 pa-
tient (1.3 %) experienced a grade 4 infusion-related
reaction; these events were possibly related to study drug.
Table 3 All-cause treatment-emergent adverse events occurring
in ≥10 % of patients in either arm










Patients with ≥1 TEAE 75 (97.4) 68 (95.8)
Nausea 38 (49.4) 34 (47.9)
Fatigue 35 (45.5) 36 (50.7)
Hypomagnesemia 29 (37.7) 29 (40.8)
Diarrhea 25 (32.5) 22 (31.0)
Dermatitis acneiform 25 (32.5) 19 (26.8)
Vomiting 24 (31.2) 27 (38.0)
Anemia 21 (27.3) 30 (42.3)
Hypokalemia 21 (27.3) 24 (33.8)
Neutropenia 20 (26.0) 24 (33.8)
Stomatitis 20 (26.0) 21 (29.6)
Dry skin 18 (23.4) 12 (16.9)
Constipation 17 (22.1) 24 (33.8)
Mucosal inflammation 16 (20.8) 16 (22.5)
Decreased appetite 15 (19.5) 18 (25.4)
Dehydration 13 (16.9) 17 (23.9)
Neutrophil count decreased 11 (14.3) 14 (19.7)
Rash 10 (13.0) 19 (26.8)
Weight decreased 10 (13.0) 13 (18.3)
Platelet count decreased 10 (13.0) 11 (15.5)
Insomnia 9 (11.7) 11 (15.5)
Dyspnea 8 (10.4) 12 (16.9)
Thrombocytopenia 8 (10.4) 12 (16.9)
Dizziness 8 (10.4) 11 (15.5)
Paronychia 8 (10.4) 10 (14.1)
Hyponatremia 7 (9.1) 14 (19.7)
Pyrexia 7 (9.1) 8 (11.3)
a Apart from rash (p = 0.034, 95 % CI: 0.010, 0.265), the difference between
Arm A and Arm B in the incidence of all-cause TEAEs occurring in ≥10 % of
patients in either arm was not statistically significant
Abbreviations: BI Boehringer Ingelheim, TEAE treatment-emergent adverse
event, US United States
Table 4 Summary of adverse events that significantly differed in











Arm A vs Arm B
p value (95 % CI)
Regardless of
causality
Bone pain 2 (2.6) 9 (12.7) 0.020 (0.016, 0.186)
Febrile
neutropenia
1 (1.3) 11 (15.5) 0.002 (0.054, 0.230)
Laryngeal
hemorrhage
0 (0.0) 6 (8.5) 0.010 (0.020, 0.149)
Somnolence 0 (0.0) 4 (5.6) 0.040 (0.003, 0.110)
Syncope 0 (0.0) 5 (7.0) 0.020 (0.011, 0.130)
Possibly related to
study drug
Dysgeusia 1 (1.3) 6 (8.5) 0.044 (0.002, 0.141)
Febrile
neutropenia
1 (1.3) 8 (11.3) 0.012 (0.022, 0.177)
Abbreviations: BI Boehringer Ingelheim, CI confidence interval, CTCAE Common
Terminology Criteria for Adverse Events, US United States
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No grade 4 infusion reaction events were reported in Arm
B. Approximately one-third of patients in each arm re-
ported hypomagnesemia possibly related to study drug,
mostly grade 1 or 2 in severity. Grade 3 hypomagnesemia
possibly related to study drug occurred in 3/77 patients
(3.9 %) in Arm A and 3/71 patients (4.2 %) in Arm B.
Deaths
In Arm A, there were 11 deaths during the study, of
which 3 deaths were considered possibly related to study
drug (cardiac arrest, hemorrhage intracranial, and septic
shock). In Arm B, there were 7 deaths during the study,
of which 1 death was considered possibly related to
study drug (septic shock).
Efficacy
There were no clinically meaningful differences in efficacy
between Arm A and Arm B; median OS, median PFS,
ORR, and DCR were similar in the two arms (Table 7).
Discussion
Overall, this study showed no clinically meaningful
differences in safety between patients receiving US
commercial cetuximab (Arm A) and those receiving BI-
manufactured cetuximab (Arm B), using the same thera-
peutic regimen as the EXTREME study [3]. The combin-
ation of US commercial cetuximab with cisplatin or
carboplatin plus 5-FU did not result in any unexpected
safety signals in the treatment of patients with locore-
gionally recurrent and/or metastatic SCCHN. The AEs
reported in this study are consistent with the known
safety profile of cetuximab, cisplatin/carboplatin, or 5-FU,
or with the underlying disease.
The safety profile of US commercial cetuximab (Arm A)
was similar to that of BI-manufactured cetuximab (Arm
B). All-grade, all-cause TEAEs with the highest incidences
included nausea, fatigue, and hypomagnesemia in both
arms. There were no AEs for which the incidence was sig-
nificantly higher in patients receiving US commercial
cetuximab than those receiving BI-manufactured cetuxi-
mab. Conversely, the incidence of rash, bone pain, febrile
neutropenia, laryngeal hemorrhage, somnolence, syncope
(regardless of causality), dysguesia, and febrile neutropenia
(possibly related to study drug) was significantly lower in
patients receiving US commercial cetuximab than those
receiving BI-manufactured cetuximab. These between-
group differences were not considered clinically meaning-
ful. The safety profile of US commercial cetuximab in
Table 5 Treatment-emergent adverse events of special interest for cetuximab








Arm A vs Arm B
p value (95 % CI)
Acneiform rasha Regardless of causality 42 (54.5) 40 (56.3) 0.826 (−0.142, 0.178)
Possibly related to study drug 41 (53.2) 40 (56.3) 0.706 (−0.129, 0.191)
Cardiac eventb Regardless of causality 5 (6.5) 10 (14.1) 0.128 (−0.022, 0.174)
Possibly related to study drug 2 (2.6) 6 (8.5) 0.120 (−0.015, 0.132)
Infusion reactionc Regardless of causality 6 (7.8) 5 (7.0) 0.862 (−0.077, 0.092)
Possibly related to study drug 5 (6.5) 4 (5.6) 0.826 (−0.068, 0.085)
Hypo-magnesemia Regardless of causality 29 (37.7) 29 (40.8) 0.692 (−0.126, 0.189)
Possibly related to study drug 26 (33.8) 23 (32.4) 0.859 (−0.138, 0.165)
a Composite term of 16 MedDRA Preferred Terms including dermatitis acneiform and rash
b Composite term of 39 MedDRA Preferred Terms including cardiac arrest and myocardial infarction
c Composite term of 9 MedDRA Preferred Terms including infusion-related reaction and anaphylactic shock
Abbreviations: BI Boehringer Ingelheim, CI confidence interval, MedDRA Medical Dictionary for Regulatory Activities, US United States
Table 6 Grade 3/4 infusion reactions
















1 (1.3) 1 (1.4)
Possibly related
to study drug





3 (3.9) 0 (0)
Possibly related
to study drug





0 (0) 1 (1.4)
Possibly related
to study drug
0 (0) 1 (1.4)
Pyrexia Regardless of
causality
0 (0) 0 (0)
Possibly related
to study drug
0 (0) 0 (0)
Abbreviations: BI Boehringer Ingelheim, US United States
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combination with chemotherapy in the current study is
also consistent with that previously observed for BI-
manufactured cetuximab in combination with the same
chemotherapy regimen in the EXTREME study [3]. Com-
monly reported AEs (>10 %) in both studies included neu-
tropenia, thrombocytopenia, and anemia, which are
typically associated with cisplatin/carboplatin and 5-FU
treatment [8–10]. In the current study, the incidence of fe-
brile neutropenia (by maximum CTCAE grade and by
grade 3/4) was 1.3 % in patients receiving US commercial
cetuximab and 15.5 % in patients receiving BI-
manufactured cetuximab. In the EXTREME study, the in-
cidence of grade 3/4 febrile neutropenia was 5 % in both
the cetuximab plus chemotherapy and chemotherapy-
alone groups [3].
There were no significant differences in the incidence
of AEs of special interest for cetuximab (acneiform rash,
cardiac events, infusion reactions, and hypomagnesemia)
[5] between patients receiving US commercial cetuximab
and those receiving BI-manufactured cetuximab. As re-
ported in other studies of cetuximab [3, 4, 11], the ma-
jority of skin reactions reported in both arms in the
current study were grade 1 or 2 in severity. Overall, the
frequency and nature of cardiac events, infusion reac-
tions, and hypomagnesemia observed in patients receiv-
ing US commercial cetuximab in the current study are
consistent with the known safety profile of cetuximab
[5]. In the EXTREME study, the incidence of cardiac
events was approximately 9 % in both the cetuximab
plus chemotherapy group and the chemotherapy-alone
group; the incidence of death attributed to cardiovascu-
lar death or sudden death was 3 % and 2 % in the cetuxi-
mab plus chemotherapy group and chemotherapy-alone
group, respectively [5]. In the same study, the incidence
of hypomagnesemia was 14 % and 6 % in the subset of
patients receiving cetuximab plus cisplatin and 5-FU and
the subset of patients receiving cisplatin and 5-FU alone,
respectively; the incidence of grade 3/4 hypomagnesemia
was 7 % and 2 %, respectively [5].
Compliance and study treatment exposure to cetuxi-
mab, as assessed by median duration of treatment and
cumulative dose of cetuximab, were similar in the two
arms. The relative dose intensity was more than 85 % for
both US commercial cetuximab and BI-manufactured
cetuximab during the combination chemotherapy period.
The relative dose intensities of cisplatin, carboplatin,
and 5-FU were also high in both treatment arms, ran-
ging from around 80 % to 95 %, suggesting that the
various combinations of agents used in this study
were well tolerated. These results are consistent with
the observation in the EXTREME study that the
addition of cetuximab to cisplatin/carboplatin plus 5-FU
did not affect the tolerability of the chemotherapy
regimen [3]. In the EXTREME study, the median
(interquartile range) duration of cisplatin and carbo-
platin treatment in the cetuximab arm was 15 weeks
(6 to 19) and 18 weeks (10 to 19), respectively [3].
The relative dose intensity of cisplatin was ≥80 % in
89 % of patients and the relative dose intensity of
carboplatin was ≥80 % in 93 % of patients in the
cetuximab arm in the EXTREME study [3].
There were no clinically meaningful differences in OS,
PFS, ORR, or DCR between patients receiving US com-
mercial cetuximab and those receiving BI-manufactured
cetuximab. While it should be noted that the current
study was not designed or powered to assess efficacy,
the efficacy results of this study are consistent with those
reported in the EXTREME study. Median OS with US
commercial cetuximab and BI-manufactured cetuximab
was 9.23 months and 9.46 months, respectively, in the
current study and 10.1 months with BI-manufactured
cetuximab in the EXTREME study [3]. Median PFS with
US commercial cetuximab and BI-manufactured cetuxi-
mab was 4.70 months and 5.65 months, respectively, in
the current study and 5.6 months with BI-manufactured
cetuximab in the EXTREME study [3]. The ORR with
US commercial cetuximab and BI-manufactured cetuxi-
mab was 29.9 % and 36.6 %, respectively, in the current
Table 7 Summary of efficacy outcomes







Arm A vs Arm B
(95 % CI; p value)
OS (months), median (95 % CI) 9.23 (7.10, 11.80) 9.46 (6.87, 11.43) 0.92 (0.619, 1.368; p = 0.681)
PFS (months), median (95 % CI) 4.70 (3.52, 5.82) 5.65 (4.04, 6.47) 1.04 (0.717, 1.497; p = 0.850)
Overall response rate, % (95 % CI) 29.9 (19.6, 40.1) 36.6 (25.4, 47.8) NA
Disease control rate, % (95 % CI) 58.4 (47.4, 69.4) 62.0 (50.7, 73.3) NA
Complete response, n (%) 3 (3.9) 3 (4.2) NA
Partial response, n (%) 20 (26.0) 23 (32.4) NA
Stable disease, n (%) 22 (28.6 %) 18 (25.4 %) NA
Abbreviations: BI Boehringer Ingelheim, CI confidence interval, HR hazard ratio, NA not applicable, OS overall survival, PFS progression-free survival, US
United States
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study and 36 % with BI-manufactured cetuximab in the
EXTREME study.
A strength of the current study was analyzing the safety
of two formulations of a drug in a randomized controlled
trial. A limitation of the study was that the sample size
was based on practical and clinical considerations. This
was done to ensure that assessment of the safety profile
could be appropriately compared between the two treat-
ment arms, rather than on any statistical assumptions or
hypotheses. However, the planned sample size was not
met because the supply of BI-manufactured cetuximab
under evaluation expired during the study. In addition,
not all patients in Arm B received BI-manufactured cetux-
imab for the duration of the study: 9/71 patients in Arm B
were switched to US commercial cetuximab when the
supply of BI-manufactured cetuximab expired. The poten-
tial bias that this may have introduced was addressed by
choosing the earliest date that a patient on Arm B was
switched from BI-manufactured cetuximab to US com-
mercial cetuximab as the cut-off date for the primary
safety analysis. However, this early cut-off date also limited
the duration of the safety period for this analysis.
Conclusions
The safety profile of US commercial cetuximab in patients
with locoregionally recurrent and/or metastatic SCCHN is
consistent with the safety profile of BI-manufactured cetux-
imab in the current study and that reported in the previ-
ously published EXTREME study [3]. The combination of
US commercial cetuximab with cisplatin or carboplatin
plus 5-FU did not result in any unexpected safety signals;
the AEs reported in this study are consistent with the
known safety profile of cetuximab, cisplatin/carboplatin, or
5-FU, or with the underlying disease. In addition, there
were no clinically meaningful differences in OS, PFS, or
ORR between patients receiving US commercial cetuximab
and those receiving BI-manufactured cetuximab. These
results indicate that, despite potentially higher systemic
exposures with US commercial cetuximab relative to BI-
manufactured cetuximab, the safety profile of US commer-
cial cetuximab is consistent with the safety profile of cetuxi-
mab in the current US prescribing information [5].
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